

May 11, 2011
Seikagaku Corporation
(Securities Code: 4548)

Notice Regarding Lawsuits to Seikagaku

Tokyo, Japan, May 11, 2011 - Seikagaku Corporation (hereafter "Seikagaku") today announces that Seikagaku and Associates of Cape Cod, Inc. (hereafter "ACC"), a U.S. subsidiary of Seikagaku, were filed two lawsuits against at the United States District Court for the District of Massachusetts. While ACC has been served the complaints, Seikagaku has not yet been served them.

1. Date of the lawsuits filed (U.S. time)

(1) The first one: April 14, 2011

(2) The second one: April 26, 2011

(ACC received both the two complaints on April 28, 2011)

2. Plaintiff

Genzyme Corporation (hereafter "Genzyme")

3. Defendants

Seikagaku (head office: Chiyoda-ku, Tokyo), ACC (head office: Massachusetts, U.S.A.), Zimmer Holdings Inc. (head office: Indiana, U.S.A.), and its three related companies. (Zimmer, Inc., Zimmer U.S. Inc., and Zimmer New England, Inc.)

4. Cause and description of the lawsuits

Genzyme filed the lawsuits asserting that Gel-One[®] Cross-linked Hyaluronate, a medical device for the treatment of pain in osteoarthritis of the knee, infringes two patents owned by Genzyme. Seikagaku received approval to market Gel-One[®] Cross-linked Hyaluronate from the U.S. Food and Drug Administration (FDA) in March of this year but has not yet launched the product at this time. Seikagaku entered into a distribution agreement with Zimmer Inc., in May 2009.

5. Future outlook

After Seikagaku has been formally served with the complaints, it is our policy that we will vigorously defend Gel-One[®] Cross-linked Hyaluronate through appropriate legal procedures. We will inform you once there will be an impact on our business performance.

#####